| 1 |
Tung JK, Jangam D, Ho CC, Fung E, Khodadoust MS, Kim YH, Zehnder JL, Stehr H, Zhang BM. Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor. J Mol Diagn 2023:S1525-1578(23)00045-4. [PMID: 36870603 DOI: 10.1016/j.jmoldx.2023.02.002] [Reference Citation Analysis]
|
| 2 |
Hanel W, Chung C, Reneau JC. Mycosis Fungoides and Sézary Syndrome. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm121.pub2] [Reference Citation Analysis]
|
| 3 |
Elliott J, Ahlawat S, Prince HM, Kennedy G, Wells J, Huang G, Collins J, Bardy P, Van Der Weyden C, Ritchie D, Khot A. Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. Bone Marrow Transplant 2022. [PMID: 36028756 DOI: 10.1038/s41409-022-01787-3] [Reference Citation Analysis]
|
| 4 |
Jakuboski S, Doyle T, Tawa M, Fisher DC, Leboeuf N, Larocca C. Inpatient Considerations in the Diagnosis and Management of the Cutaneous T-Cell Lymphoma Patient. Curr Derm Rep. [DOI: 10.1007/s13671-022-00367-4] [Reference Citation Analysis]
|
| 5 |
Dworkin ML, Jiang AL, Von Eyben R, Spinner MA, Advani RH, Lowsky R, Hiniker SM, Hoppe RT. Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant. Bone Marrow Transplant 2022;57:106-12. [PMID: 34671121 DOI: 10.1038/s41409-021-01495-4] [Reference Citation Analysis]
|
| 6 |
Kim YH. What factors guide treatment selection in mycosis fungoides and Sezary syndrome? Hematology Am Soc Hematol Educ Program 2021;2021:303-12. [PMID: 34889422 DOI: 10.1182/hematology.2021000263] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Franke G, Dumann K, Jentzsch M, Monecke A, Doehring C, Nehring-vucinic C, Schwind S, Niederwieser D, Platzbecker U, Ziemer M, Vucinic V. Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome. Front Oncol 2021;11:749691. [DOI: 10.3389/fonc.2021.749691] [Reference Citation Analysis]
|
| 8 |
Stamouli M, Gkirkas K, Karagiannidi A, Iliakis T, Chondropoulos S, Thomopoulos T, Nikolaou V, Pappa V, Papadavid E, Tsirigotis P. Allogeneic Stem Cell Transplantation with a Novel Reduced Intensity Conditioning Regimen for the Treatment of Patients with Primary Cutaneous T-cell Lymphomas. Clin Hematol Int 2021;3:72-6. [PMID: 34595469 DOI: 10.2991/chi.k.210529.001] [Reference Citation Analysis]
|
| 9 |
Applewaite R, Scarisbrick J. Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma at a tertiary care centre. European Journal of Cancer 2021;156:S55. [DOI: 10.1016/s0959-8049(21)00728-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Gisriel SD, Hung KW, Braddock DT, Seropian S, Foss FM, Robert ME, Xu ML. Simultaneous colonic T-cell lymphoma and graft-versus-host disease: A rare diagnosis. Human Pathology: Case Reports 2021;24:200507. [DOI: 10.1016/j.ehpc.2021.200507] [Reference Citation Analysis]
|
| 11 |
Thompson LL, Pan CX, Chang MS, Molina GE, Chen YB, Barnes JA, Chen ST. Alemtuzumab, total skin electron beam, and non-myeloablative allogeneic haematopoietic stem-cell transplantation in advanced sezary syndrome: a retrospective cohort study. J Eur Acad Dermatol Venereol 2021;35:e373-5. [PMID: 33545747 DOI: 10.1111/jdv.17144] [Reference Citation Analysis]
|
| 12 |
Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
